Image source: Inte Pharma
Congenital pharmacy ( IPHA; Euronext: IPH) announced this
AstraZeneca ( AZN) was given to the first patient in his phase 3 clinical trial, evaluating durvalumab in combination with monalizumab
or oleclumab AstraZeneca in patients with inoperable stage III non-small cell lung cancer (NSCLC) who have not progressed after final concomitant platinum-based chemotherapy.
This is an important milestone for Inate Pharma and the latest payment in a fruitful partnership with AstraZeneca, which has brought in $ 450 million since the deal began in 2015.
Phase 3 clinical trial
The aim of Phase 3 “PACIFIC-9” is to determine whether the addition of monalizumab or oleculum to durvalumab improves outcomes for patients.
Monalizumab, Inate’s lead partner, is an immune checkpoint inhibitor targeting NKG2A receptors expressed on cytotoxic CD8 + CD8 + T cells and natural killer cells (NK).
Durvalumab (Imfinzi) from AstraZeneca is the world standard for the treatment of inoperable stage III NSCLC in patients whose disease has not progressed after chemotherapy. Durvalumab is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with PD-1 and CD80 proteins, counteracting tumor immune tactics and releasing inhibition of immune responses.
Oclelumab is the AstraZeneca monoclonal antibody under study, which selectively binds to and inhibits CD73 activity overexpressed in tumors.
AstraZeneca is looking to recruit patients to more than 200 centers in the coming months.
Strong results of phase 2
The results of an interim analysis of phase 2 data showed that monalizumab in combination with durvalumab increased the objective response rate (ORR) and long-term progression-free survival (PFS) compared with durvalumab alone.
Detailed results were originally presented during the European Society of Medical Oncology (ESMO) Congress in 2021 in September 2021 (see chart below to learn about stocks related to this data analysis) and were published in the Journal of Clinical Oncology last week.
- Pharma’s innate investors haven’t had much reason to rejoice since the unrest last September when AstraZeneca released positive Phase 2 data, but this latest $ 50 million payout trigger should boost the stock.
- The stock is already trading 9% higher on Friday before market trading. Even with such an increase, the market capitalization is only $ 234 million, making shares of Inate Pharma an inexpensive call option in a wide and deep pipeline of anti-cancer therapies.
- The agreement with AstraZeneca has already led to the payment of $ 450 million to Inate Pharma
- Shows that the clinical team is progressing steadily.
- Inate Pharma can still earn up to $ 825 million on additional clinical and commercial stages in addition to fees.
- The market for stage III NSCLC is sadly huge: an estimated 2.2 million people worldwide have been diagnosed with lung cancer, and 80-85% of these patients are classified as NSCLC.
- Stage III NSCLC accounts for approximately one-quarter of NSCLC cases, and most of these patients are diagnosed with inoperable tumors.
Source: Stock news
Share price data is provided by IEX Cloud with a 15-minute delay. Chart cost data is provided by TradingView with a 15-minute delay.
This article is first published on Source link